An observational study in Peritonitis and Peritonitis Bacterial, sponsored by University of Colorado, Denver. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-09.
Sponsored by University of Colorado, Denver · Observational
This study evaluates the use of Dalbavancin 1500 mg IV x 1 dose for treating patients with gram positive peritonitis in patients requiring peritoneal dialysis.
189 studies on the registry are indexed under Peritonitis; 26 are open to participants now.
This study's enrollment of 2 is below the median of 125 across 60 observational studies indexed under Peritonitis.
Browse Peritonitis studies →University of Colorado, Denver is the lead sponsor of 1,538 studies on the registry; 318 are open to participants now.
Of its 146 completed or terminated interventional studies of FDA-regulated products, 92 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients currently receiving peritoneal dialysis that are found to have bacterial peritonitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients > 18 years of age actively receiving peritoneal dialysis diagnosed with a gram + peritonitis determined to be a good candidate for dalbavancin treatment by the attending nephrology attending.
Exclusion Criteria:
Patients with contraindications to dalbavancin therapy
Dalbavancin 1500 mg intravenously x 1 dose
Clinical cure
resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality
Time frame: 14 days
Clinical cure
resolution of signs and symptoms (e.g. abdominal pain), bacterial eradication, reduction in clinical markers (e.g. peritoneal fluid findings, CRP, etc), and return of peritoneal dialysis functionality
Time frame: 28 days
Treatment emergent adverse events
Occurrence of any adverse events
Time frame: 14 days
Treatment emergent adverse events
Occurrence of any adverse events
Time frame: 28 days
Plan to share: No
Ran from Jun 2020 to primary completion in Dec 2023, 42 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver →